Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC610 Vaccine for Herpes Zoster Prevention
NCT05769049Phase 1Completed
- Sponsor
- Recbio
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REC610 in herpes zoster (HZ) (2 arms), sponsored by Recbio. Primary endpoints: Incidence of related Adverse Events, Incidence of solicited Adverse Events and 3 more. Started Feb 2023; status: completed.
02
Drugs
REC610
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05769049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769049.